Spots Global Cancer Trial Database for recurrent squamous cell carcinoma of the larynx

Every month we try and update this database with for recurrent squamous cell carcinoma of the larynx cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00639769	Head and Neck C...	cisplatin irinotecan hydr...	18 Years -	Vanderbilt-Ingram Cancer Center
Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	NCT00003809	Head and Neck C...	cetuximab cisplatin	18 Years - 120 Years	Eastern Cooperative Oncology Group
Biomarkers in Patients With Head and Neck Cancer	NCT01466257	Head and Neck C...	cetuximab cisplatin DNA analysis gene expression... mutation analys... laboratory biom...	18 Years - 120 Years	Eastern Cooperative Oncology Group
Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors	NCT00006036	Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu...	cisplatin lurtotecan lipo...	18 Years - 120 Years	Canadian Cancer Trials Group
Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function	NCT00002901	Breast Cancer Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu...	docetaxel	18 Years -	City of Hope Medical Center
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer	NCT00470496	Recurrent Adeno... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Thyro... Recurrent Verru... Recurrent Verru... Stage I Adenoid... Stage I Basal C... Stage I Esthesi... Stage I Follicu... Stage I Inverte... Stage I Lymphoe... Stage I Lymphoe... Stage I Midline... Stage I Mucoepi... Stage I Papilla... Stage I Salivar... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Verruco... Stage I Verruco... Stage II Adenoi... Stage II Basal ... Stage II Esthes... Stage II Follic... Stage II Invert... Stage II Lympho... Stage II Lympho... Stage II Midlin... Stage II Mucoep... Stage II Papill... Stage II Saliva... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Verruc... Stage II Verruc...	HPPH photodynamic th... conventional su...	18 Years -	Roswell Park Cancer Institute
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer	NCT00040807	Head and Neck C...	docetaxel irinotecan hydr...	18 Years - 120 Years	Eastern Cooperative Oncology Group
NGR-TNF in Treating Patients With Advanced Solid Tumors	NCT00098943	Colorectal Canc... Head and Neck C... Kidney Cancer Unspecified Adu...	CNGRC peptide-T...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery	NCT00276523	Head and Neck C...	PEG-interferon ... Conventional su... Neoadjuvant the...	18 Years -	M.D. Anderson Cancer Center
Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy	NCT00004865	Head and Neck C...	cetuximab cisplatin fluorouracil paclitaxel	18 Years -	National Cancer Institute (NCI)
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors	NCT00066651	Cervical Cancer Fallopian Tube ... Head and Neck C... Lung Cancer Malignant Mesot... Ovarian Cancer Pancreatic Canc... Primary Periton...	SS1(dsFv)-PE38 ...	18 Years -	National Cancer Institute (NCI)
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer	NCT00006107	Head and Neck C...	Taxotere Surgery radiation thera...	18 Years -	Dana-Farber Cancer Institute
Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer	NCT00023959	Metastatic Squa... Recurrent Adeno... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage III Adeno... Stage III Basal... Stage III Esthe... Stage III Inver... Stage III Lymph... Stage III Lymph... Stage III Midli... Stage III Mucoe... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Adenoi... Stage IV Basal ... Stage IV Esthes... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Untreated Metas...	hydroxyurea fluorouracil bevacizumab radiation thera... filgrastim laboratory biom...	18 Years -	National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00020189	Head and Neck C... Thromboembolism	acetylsalicylic... alvocidib clopidogrel bis...	18 Years -	National Cancer Institute (NCI)
3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx	NCT00757549	Head and Neck C...	cetuximab cisplatin TdT-mediated dU... 3'-deoxy-3'-[18... immunohistochem... laboratory biom... fludeoxyglucose... radiation thera...	18 Years - 120 Years	Mayo Clinic
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00507767	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	dasatinib pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer	NCT00482872	Head and Neck C...	gene expression... mutation analys... polymerase chai... polymorphism an... flow cytometry laboratory biom...	18 Years - 120 Years	Vanderbilt University Medical Center
Study of Blood and Tissue Samples From Patients With Larynx Cancer, Pharynx Cancer, or Oral Cavity Cancer	NCT00963326	Head and Neck C...	laboratory biom...	15 Years -	National Cancer Institute (NCI)
Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer	NCT00002659	Head and Neck C...	cisplatin-e the...	18 Years -	National Cancer Institute (NCI)
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00425750	Head and Neck C...	bortezomib docetaxel laboratory biom... pharmacological...	18 Years -	Vanderbilt-Ingram Cancer Center
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00096512	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	sorafenib tosyl... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer	NCT00005035	Head and Neck C...	oxaliplatin	18 Years -	National Cancer Institute (NCI)
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer	NCT00470496	Recurrent Adeno... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Thyro... Recurrent Verru... Recurrent Verru... Stage I Adenoid... Stage I Basal C... Stage I Esthesi... Stage I Follicu... Stage I Inverte... Stage I Lymphoe... Stage I Lymphoe... Stage I Midline... Stage I Mucoepi... Stage I Papilla... Stage I Salivar... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Verruco... Stage I Verruco... Stage II Adenoi... Stage II Basal ... Stage II Esthes... Stage II Follic... Stage II Invert... Stage II Lympho... Stage II Lympho... Stage II Midlin... Stage II Mucoep... Stage II Papill... Stage II Saliva... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Verruc... Stage II Verruc...	HPPH photodynamic th... conventional su...	18 Years -	Roswell Park Cancer Institute
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)	NCT00031681	Advanced Adult ... Carcinoma of th... Estrogen Recept... Extensive Stage... Gastrointestina... HER2-negative B... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Progesterone Re... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Borde... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Endom... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Border... Stage IV Breast... Stage IV Colon ... Stage IV Endome... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Cervi... Stage IVB Cervi... Triple-negative... Unresectable Ex... Unresectable Ga... Unspecified Adu... Untreated Metas...	7-hydroxystauro... irinotecan hydr... diagnostic labo...	18 Years -	National Cancer Institute (NCI)
DNA Analysis of Tissue Samples From Patients With Head and Neck Cancer	NCT00898664	Head and Neck C...	cytogenetic ana... gene expression... mutation analys... polymerase chai... immunohistochem... laboratory biom...	18 Years -	Vanderbilt-Ingram Cancer Center
Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function	NCT00002901	Breast Cancer Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu...	docetaxel	18 Years -	City of Hope Medical Center
Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases	NCT00062348	Colorectal Canc... Head and Neck C... Metastatic Canc...	boronophenylala... sodium borocapt... conventional su...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function	NCT00002901	Breast Cancer Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu...	docetaxel	18 Years -	City of Hope Medical Center
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery	NCT00113399	Head and Neck C...	filgrastim cisplatin docetaxel fluorouracil paclitaxel radiation thera...	18 Years -	Radiation Therapy Oncology Group
Study of Blood and Tissue Samples From Patients With Larynx Cancer, Pharynx Cancer, or Oral Cavity Cancer	NCT00963326	Head and Neck C...	laboratory biom...	15 Years -	National Cancer Institute (NCI)
Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx	NCT00004227	Head and Neck C...	cetuximab conventional su... radiation thera...	18 Years -	University of Alabama at Birmingham
Radiation Therapy Following Surgery in Treating Patients With Recurrent or Second Primary Cancer of the Head and Neck Following Previous Radiation Therapy	NCT00004226	Head and Neck C...	radiation thera...	18 Years -	National Cancer Institute (NCI)
Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer	NCT00629226	Head and Neck C...	cetuximab bortezomib cisplatin intensity-modul...	18 Years -	National Institutes of Health Clinical Center (CC)
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck	NCT00063895	Recurrent Non-s... Recurrent Ovari... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage IIIA Non-... Stage IIIA Ovar... Stage IIIB Non-... Stage IIIB Ovar... Stage IIIC Ovar... Stage IV Non-sm... Stage IV Ovaria... Stage IV Squamo... Stage IV Squamo... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam...	erlotinib hydro... pharmacological... pharmacogenomic... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	NCT02035527	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Oral ... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	sorafenib tosyl... cisplatin docetaxel Correlative Stu...	18 Years -	Ohio State University Comprehensive Cancer Center
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	NCT00041171	Adult Solid Tum... Breast Cancer Head and Neck C... Kidney and Urin... Male Reproducti... Thorax and Resp...	Hypericum perfo... docetaxel placebo	18 Years - 120 Years	Alliance for Clinical Trials in Oncology
AP5346 or Oxaliplatin in Treating Patients With Metastatic and/or Unresectable Recurrent Head and Neck Cancer	NCT00415298	Head and Neck C...	DACH polymer pl... oxaliplatin gene expression... immunohistochem... pharmacological... biopsy	18 Years -	National Cancer Institute (NCI)
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors	NCT00089362	Male Breast Can... Recurrent Adeno... Recurrent Basal... Recurrent Breas... Recurrent Colon... Recurrent Esthe... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Melan... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage III Adeno... Stage III Basal... Stage III Colon... Stage III Esthe... Stage III Gastr... Stage III Inver... Stage III Lymph... Stage III Lymph... Stage III Melan... Stage III Midli... Stage III Mucoe... Stage III Ovari... Stage III Renal... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IIIB Brea... Stage IIIC Brea... Stage IV Adenoi... Stage IV Basal ... Stage IV Breast... Stage IV Colon ... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Melano... Stage IV Midlin... Stage IV Mucoep... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Unspecified Adu... Untreated Metas...	alvespimycin hy... laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer	NCT00897793	Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Prostate Cancer	venipuncture radiation thera...	18 Years -	Vanderbilt-Ingram Cancer Center
Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer	NCT00281866	Head and Neck C...	erlotinib hydro...	18 Years - 120 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Docetaxel in Treating Patients With Solid Tumors	NCT00003565	Bladder Cancer Breast Cancer Head and Neck C... Lung Cancer Unspecified Adu...	docetaxel	18 Years -	Alliance for Clinical Trials in Oncology
Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer	NCT00898742	Head and Neck C...	DNA and tissue ... reverse transcr... mass spectromet...	-	Vanderbilt-Ingram Cancer Center
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00425750	Head and Neck C...	bortezomib docetaxel laboratory biom... pharmacological...	18 Years -	Vanderbilt-Ingram Cancer Center
Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer	NCT00003251	Drug/Agent Toxi... Head and Neck C... Radiation Toxic...	amifostine trih... cisplatin paclitaxel radiation thera...	18 Years -	National Cancer Institute (NCI)
Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery	NCT00738868	Head and Neck C...	cetuximab stereotactic bo...	18 Years -	National Cancer Institute (NCI)
Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy	NCT01728480	Mucositis Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Squamo... Stage IV Squamo... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	entolimod intensity-modul... cisplatin pharmacological... laboratory biom...	18 Years -	Roswell Park Cancer Institute
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	NCT00337129	Head and Neck C...	eribulin mesyla...	18 Years -	National Cancer Institute (NCI)
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00507767	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	dasatinib pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy	NCT02123511	Mucositis Oral Complicati... Recurrent Adeno... Recurrent Basal... Recurrent Lymph... Recurrent Lymph... Recurrent Mucoe... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage I Adenoid... Stage I Basal C... Stage I Lymphoe... Stage I Lymphoe... Stage I Mucoepi... Stage I Salivar... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Verruco... Stage I Verruco... Stage II Adenoi... Stage II Basal ... Stage II Lympho... Stage II Lympho... Stage II Mucoep... Stage II Saliva... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Verruc... Stage II Verruc... Stage III Adeno... Stage III Basal... Stage III Lymph... Stage III Lymph... Stage III Mucoe... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Lympho... Stage IV Squamo... Stage IVA Adeno... Stage IVA Basal... Stage IVA Lymph... Stage IVA Mucoe... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Adeno... Stage IVB Basal... Stage IVB Lymph... Stage IVB Mucoe... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Adeno... Stage IVC Basal... Stage IVC Lymph... Stage IVC Mucoe... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	acetylcysteine placebo quality-of-life... questionnaire a...	18 Years -	Mayo Clinic
Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer	NCT00891904	Head and Neck C...	cetuximab stereotactic bo...	18 Years - 120 Years	Roswell Park Cancer Institute
Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer	NCT00896675	Head and Neck C...	proteomic profi... proteomic profi...	-	Vanderbilt-Ingram Cancer Center
Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer	NCT00899821	Head and Neck C...	aldesleukin recombinant int... sargramostim immunologic tec... biopsy	20 Years - 80 Years	NYU Langone Health
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors	NCT00526149	Breast Cancer Endometrial Can... Head and Neck C... Melanoma (Skin) Ovarian Cancer Sarcoma	BI 2536 high performanc... mass spectromet... pharmacological...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00639769	Head and Neck C...	cisplatin irinotecan hydr...	18 Years -	Vanderbilt-Ingram Cancer Center
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy	NCT01156142	Head and Neck C... Mucositis Oral Complicati... Pain	doxepin hydroch... placebo	18 Years -	Alliance for Clinical Trials in Oncology
Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer	NCT00006033	Head and Neck C...	gene therapy interleukin-2 g... methotrexate	18 Years -	National Cancer Institute (NCI)
Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery	NCT00738868	Head and Neck C...	cetuximab stereotactic bo...	18 Years -	National Cancer Institute (NCI)
Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx	NCT00004234	Head and Neck C... Oral Complicati...	management of t... radiation thera...	16 Years - 120 Years	Canadian Cancer Trials Group
Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer	NCT01313390	Head and Neck C...	docetaxel everolimus laboratory biom... pharmacological...	18 Years -	University College, London
Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx	NCT00004234	Head and Neck C... Oral Complicati...	management of t... radiation thera...	16 Years - 120 Years	Canadian Cancer Trials Group
Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy	NCT00003856	Head and Neck C...	temoporfin	18 Years -	National Cancer Institute (NCI)
Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck	NCT00083057	Head and Neck C...	gefitinib paclitaxel radiation thera...	18 Years -	National Institutes of Health Clinical Center (CC)
Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	NCT00114283	Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	lapatinib ditos... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer	NCT00482872	Head and Neck C...	gene expression... mutation analys... polymerase chai... polymorphism an... flow cytometry laboratory biom...	18 Years - 120 Years	Vanderbilt University Medical Center
Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors	NCT00006036	Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu...	cisplatin lurtotecan lipo...	18 Years - 120 Years	Canadian Cancer Trials Group
L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer	NCT01155609	Mucositis Oral Complicati... Oral Complicati... Recurrent Adeno... Recurrent Basal... Recurrent Lymph... Recurrent Lymph... Recurrent Mucoe... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage I Adenoid... Stage I Basal C... Stage I Lymphoe... Stage I Lymphoe... Stage I Mucoepi... Stage I Salivar... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Verruco... Stage I Verruco... Stage II Adenoi... Stage II Basal ... Stage II Lympho... Stage II Lympho... Stage II Mucoep... Stage II Saliva... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Verruc... Stage II Verruc... Stage III Adeno... Stage III Basal... Stage III Lymph... Stage III Lymph... Stage III Mucoe... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Adenoi... Stage IV Basal ... Stage IV Lympho... Stage IV Lympho... Stage IV Mucoep... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc...	quality-of-life... management of t... L-lysine	18 Years -	University of Washington
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab	NCT00939627	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	cetuximab placebo sorafenib tosyl... laboratory biom... quality-of-life...	18 Years -	National Cancer Institute (NCI)
Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer	NCT00896675	Head and Neck C...	proteomic profi... proteomic profi...	-	Vanderbilt-Ingram Cancer Center
Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck	NCT00906360	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Tongue Cancer Untreated Metas...	sunitinib malat... pharmacological... 3-dimensional c... cetuximab	18 Years -	National Cancer Institute (NCI)
Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck	NCT00081211	Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Salivary Gland ... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo...	PV701	18 Years -	National Cancer Institute (NCI)
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer	NCT00397384	Adenocarcinoma ... Adenocarcinoma ... Advanced Adult ... Carcinoma of th... Gastrointestina... Metastatic Gast... Metastatic Squa... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Colon... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Pancr... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Colon ... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Pancre... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Tongue Cancer Unresectable Ex... Unresectable Ga...	cetuximab erlotinib hydro... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx	NCT00675233	Head and Neck C...	HPPH laser therapy	18 Years -	Roswell Park Cancer Institute
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer	NCT00004901	Head and Neck C...	ethynyluracil fluorouracil hydroxyurea radiation thera...	18 Years -	National Cancer Institute (NCI)
Arginine/Omega-3 Fatty Acids/Nucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy	NCT00559156	Head and Neck C...	arginine/omega-... cisplatin adjuvant therap... radiation thera...	18 Years -	National Cancer Institute (NCI)
Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer	NCT00891904	Head and Neck C...	cetuximab stereotactic bo...	18 Years - 120 Years	Roswell Park Cancer Institute
Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer	NCT00248560	Head and Neck C...	docetaxel Gemcitabine	18 Years - 120 Years	Barbara Ann Karmanos Cancer Institute
Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer	NCT00509665	Head and Neck C...	doxorubicin hyd... gemcitabine hyd...	18 Years - 120 Years	Medical University of South Carolina
Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer	NCT00448552	Head and Neck C...	capecitabine oxaliplatin	18 Years - 120 Years	University of Miami
Immunotoxin Therapy in Treating Patients With Advanced Cancer	NCT00006981	Cervical Cancer Fallopian Tube ... Head and Neck C... Lung Cancer Malignant Mesot... Ovarian Cancer Pancreatic Canc... Primary Periton...	SS1(dsFv)-PE38 ...	18 Years -	National Cancer Institute (NCI)
Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer	NCT00573989	Head and Neck C...	erlotinib hydro... pemetrexed diso... quality-of-life... intensity-modul...	18 Years - 120 Years	Wake Forest University Health Sciences

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: